COVID-19 vaccine

Statement from VUMC: COVID-19 vaccination continues to be the way forward

Last week, Vanderbilt University Medical Center announced that COVID-19 vaccinations for leaders will become mandatory. This was a carefully considered step forward in VUMC’s ongoing efforts to protect its patients and employees from the SARS-CoV-2 virus and its variants.

Community hospitals shine in vaccine distribution

Vanderbilt University Medical Center’s community hospitals — Vanderbilt Wilson County Hospital (VWCH), Vanderbilt Bedford Hospital and Vanderbilt Tullahoma-Harton Hospital — have risen to the occasion to meet critical vaccination needs across Tennessee.

Heparin, platelets discouraged as treatment for blood clots after COVID vaccine

Heparin and platelets are discouraged as treatment for patients who develop blood clots in the brain and low platelet counts 6-15 days after receiving Johnson & Johnson’s Janssen COVID-19 vaccine, following a clinical investigation review of 12 U.S. cases conducted by the CDC and institutions including Vanderbilt University Medical Center.

Vaccinated patients avoiding hospital stays as pandemic rages on

Vanderbilt University Medical Center (VUMC) is reporting only four persons who have been fully vaccinated against COVID-19 have been diagnosed with COVID during an acute care hospitalization at its facilities over the past four months.

James Crowe Jr., MD, and colleagues are exploring how the body’s immune system gears up to fight off infection.

Crowe receives SEC Faculty Achievement Award

James Crowe Jr., MD, a physician-scientist on the front lines of global research to eliminate human susceptibility to COVID-19 and other illnesses, is Vanderbilt University’s winner of the 2021 Southeastern Conference Faculty Achievement Award.

Vials with medication and syringe on blue methacrylate table. Horizontal composition. Top elevated view.

Investigational vaccine to be tested against COVID-19 variant

Vanderbilt University Medical Center is participating in a national phase 1 clinical trial in healthy adults of an investigational vaccine against the B.1.351 variant of the COVID-19 virus that was first identified in South Africa.

1 2 3 4 5